PPARs and nonalcoholic fatty liver disease.

Abstract

Nonalcoholic fatty liver disease (NAFLD) encompasses a range of liver pathology ranging from simple steatosis to varying degrees of inflammation, hepatocyte injury and fibrosis. Without intervention it can progress to end-stage liver disease and hepatocellular carcinoma. Given its close association with obesity, the prevalence of NAFLD has increased dramatically worldwide. Currently, there are no FDA-approved medications for the treatment of NAFLD and although lifestyle modifications with appropriate diet and exercise have been shown to be beneficial, this has been difficult to achieve and sustain for the majority of patients. As such, the search for effective therapeutic agents is an active area of research. Peroxisome proliferator-activated receptors (PPARs) belong to a class of nuclear receptors. Because of their key role in the transcriptional regulation of mediators of glucose and lipid metabolism, PPAR ligands have been investigated as possible therapeutic agents. Here we review the current evidence from preclinical and clinical studies investigating the therapeutic potential of PPAR ligands for the treatment of NAFLD.

• Authors: Kim H H Liss, Brian N Finck
• Journal: Biochimie (Biochimie) Vol. 136 Pg. 65-74 (May 2017) ISSN: 1638-6183 [Electronic] France
• PMID: 27916647 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2016 Elsevier B.V. and Société Française de Biochimie et Biologie Moléculaire (SFBBM). All rights reserved.

Chemical References

• Peroxisome Proliferator-Activated Receptors

Topics

• Animals
• Humans
• Non-alcoholic Fatty Liver Disease (drug therapy, metabolism, physiopathology)
• Peroxisome Proliferator-Activated Receptors (agonists, metabolism)